Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 35

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
Sales and Marketing    

Sales and marketing expenses were $183,110 for
the nine months ended September 30, 2025, as compared to $484,769   for the nine months ended September 30, 2024, a decrease of $301,659,
or 62%. The costs include primarily headcount and pre-selling activities for our TAEUS product line. Sales and marketing expenses decreased
largely due to continued reductions in expenses resulting from our restructuring in the second quarter of 2024. Currently, our marketing
efforts are through our website and attendance of key industry meetings.

General and Administrative    

Our general and administrative expenses for the nine months ended September
30, 2025 were $2,616,106, compared to $3,483,303 for the nine months ended September 30, 2024, a decrease of $867,197, or 25%. Our wage
and related expenses for the nine months ended September 30, 2025 were $994,098, compared to $1,079,942 for the nine months ended September
30, 2024. Wage and related expenses in the nine months ended September 30, 2025 included $296,273 of stock compensation expense related
to the issuance and vesting of options and RSUs. Our professional fees, which include legal, audit, and investor relations, for the nine
months ended September 30, 2025 were $1,031,954, compared to $1,820,454 for the nine months ended September 30, 2024.

Other Income

Other income was $282,874 for the nine months ended September 30, 2025,
compared to other expense of $838,535 for the nine months ended September 30, 2024, an increase of $1,121, 409, or 134%, due to increased
interest income. For the nine months ended September 30, 2025, there were changes in fair value of warrant liability of $203,400.

Net Loss    

As a result of the foregoing, for the nine months ended September 30,
2025, we recorded a net loss of $3,858,201, compared to a net loss of $7,358,943 for the nine months ended September 30, 2024.

Near-Term Liquidity and Capital Resources

We are experiencing financial and operating challenges. In the absence
of immediate additional liquidity for our T